153 related articles for article (PubMed ID: 38198002)
1. Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients.
Mantziari S; Farinha HT; Messier M; Winiker M; Allemann P; Ozsahin EM; Demartines N; Piessen G; Schäfer M
Ann Surg Oncol; 2024 Apr; 31(4):2499-2508. PubMed ID: 38198002
[TBL] [Abstract][Full Text] [Related]
2. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
[TBL] [Abstract][Full Text] [Related]
3. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
[No Abstract] [Full Text] [Related]
5. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
7. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.
Li Y; Liu H; Sun C; Yin X; Tong J; Zhang X; Wang X; Yuan X; Zhang Z; Lu G; Gu Y; Li Y; Huang T; Qiao Z; Chen Y
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):405-416. PubMed ID: 33964352
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
[TBL] [Abstract][Full Text] [Related]
11. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer.
Venkat PS; Shridhar R; Naghavi AO; Hoffe SE; Almhanna K; Pimiento JM; Fontaine JP; Abuodeh Y; Meredith KL; Frakes JM
Dis Esophagus; 2017 Jul; 30(7):1-9. PubMed ID: 30052899
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes.
Buckstein M; Rhome R; Ru M; Moshier E
Dis Esophagus; 2018 May; 31(5):. PubMed ID: 29309563
[TBL] [Abstract][Full Text] [Related]
13. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.
Lertbutsayanukul C; Tharavej C; Klaikeaw N; Prayongrat A; Lowanitchai C; Sriuranpong V
Thorac Cancer; 2017 May; 8(3):219-228. PubMed ID: 28322515
[TBL] [Abstract][Full Text] [Related]
14. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction.
Nusrath S; Thammineedi SR; Raju KVVN; Patnaik SC; Saksena AR; Karthik J; Basude M; Kumar J P; Shukla S; Rao VB; Kumar C K; Gujjuru S; Tewani R; Rushdie T; Sudhir R; Smith LM; Are C
J Surg Oncol; 2023 Jan; 127(1):48-55. PubMed ID: 36129433
[TBL] [Abstract][Full Text] [Related]
16. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
17. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
18. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
19. Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer.
Ising MS; Marino K; Trivedi JR; Rojan AA; Dunlap NE; van Berkel V; Fox MP
J Gastrointest Surg; 2019 Apr; 23(4):670-678. PubMed ID: 30788714
[TBL] [Abstract][Full Text] [Related]
20. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
